楽天モバイル
Randomized Phase III Trial Comparing Switch-Maintenance Pemetrexed With Observation Followed by Pemetrexed at Progression in Advanced NSCLC https://pubmed.ncbi.nlm.nih.gov/32543258/ 【目的】 2つの第III相試験では、プラチナ併用化学療法後にペ…
Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancerta https://pubmed.ncbi.nlm.nih.gov/31562796/ 背景：進行非小細胞肺癌（NSCLC）の患者を対象とした前臨床研究では、特にPD -L1において、ニボルマブとイピリムマブの併用療法の方が、ニ…
Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. https://www.ncbi.nlm.nih.gov/pubmed/31695838 背…
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). https://www.ncbi.nlm.nih.gov/pubmed/29045553 背景：分…
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study. https://www.ncbi.nlm.nih.gov/pubmed/32318871 目的：REVELでは、進行した非小細胞肺癌（aNSCLC）の患者と腫瘍の侵攻…
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L). https://www.ncbi.nlm.nih.gov/pubmed/32066647 abstract ・Chemo→ICI→Chemo vs Chemo→C…
Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion. https://www.ncbi.nlm.nih.gov/pubmed/30642552 目的：免疫チェックポイント阻害剤（ICI）は、進行した非…
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of p…
Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal Cancer. https://www.ncbi.nlm.nih.gov/pubmed/30149985 ・ベバシズマブ、ラムシルマブ、ザルトラップ3つの血…
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. …
